Kisspeptin-10 dosage in human research ranges from 1 µg/kg intravenously in early clinical studies to experimental subcutaneous protocols in more recent work. As a compounded peptide that is not FDA-approved, any protocol requires a licensed provider evaluation — there is no validated standard dose for off-label use.
Kisspeptin-10 is a neuropeptide that sits near the top of the reproductive hormone cascade. It tells the hypothalamus to release GnRH, which triggers LH and FSH, which drive testosterone and estrogen production. For anyone trying to support natural hormone function — rather than suppress it — kisspeptin is an interesting research target.
Here's a step-by-step guide to how kisspeptin-10 dosage works in research, how to reconstitute a vial, and what to expect before, during, and after any protocol approved by a licensed provider.
What Is Kisspeptin-10?
Kisspeptin is a family of peptides encoded by the KISS1 gene. Kisspeptin-10 is the 10-amino-acid active fragment — the shortest form that retains full receptor binding activity at the KiSS1 receptor (KISS1R, also called GPR54).
In human studies, intravenous kisspeptin-10 consistently stimulates LH and testosterone secretion. A 2012 study published on PubMed found that kisspeptin-10 significantly increases LH pulse frequency in men — a mechanism relevant to male hypogonadism research. A 2024 study on PubMed explored intranasal administration and found rapid LH stimulation without the need for IV access.
Research is promising — but clinical use outside a study context is still in early territory. Kisspeptin-10 is not FDA-approved for any indication.
Kisspeptin-10 Dosage Overview
| Context | Route | Dose Used in Research | Finding |
|---|---|---|---|
| LH stimulation in men | IV bolus | 1 µg/kg (max stimulation) | Significant LH and testosterone increase (PubMed 21632807) |
| Continuous infusion | IV infusion | 4 µg/kg/h for 22.5 hours | Sustained LH and testosterone elevation |
| Intranasal administration | Intranasal | 0.9–25.6 nmol/kg | Rapid LH response without IV access |
| Subcutaneous (off-label) | SubQ injection | No validated human RCT protocol | Common in peptide clinics; not studied systematically |
The subcutaneous injection model — the one most commonly used in telehealth peptide contexts — does not have a peer-reviewed validated protocol. Providers who prescribe it draw on the IV research and apply clinical judgment. This underscores why any kisspeptin-10 protocol must be supervised by a licensed provider, not self-managed.
How to Use Kisspeptin-10: Step 1 — Confirm You're a Candidate
Before any protocol starts, a licensed provider reviews your health history. Kisspeptin-10 research focuses primarily on people with documented hypogonadotropic hypogonadism, subfertility, or hormone optimization goals under medical oversight. You'll likely need baseline labs: total and free testosterone, LH, FSH, estradiol, and a metabolic panel.
Kisspeptin-10 is not appropriate for everyone. People with hormone-sensitive cancers, active reproductive conditions requiring suppression, or unmonitored cardiovascular conditions should not use it. The approval step is not a formality — it's the gate through which a legitimate protocol begins. At TelosRX, kisspeptin research and its clinical implications are reviewed as part of the asynchronous intake process.
Step 2 — Reconstitute the Vial
Kisspeptin-10 is supplied as a lyophilized (freeze-dried) powder. Before injecting, it must be reconstituted with bacteriostatic water. Here's how the process works:
- Wipe the rubber stopper on both the peptide vial and the bacteriostatic water vial with an alcohol swab. Allow to air-dry.
- Draw the appropriate volume of bacteriostatic water into a syringe. For a 5 mg kisspeptin-10 vial, adding 2.0 mL creates a concentration of 2,500 mcg/mL (2.5 mg/mL).
- Inject the water slowly down the inner wall of the peptide vial. Do not spray it directly onto the powder — this can degrade the peptide.
- Gently swirl or roll the vial until the powder fully dissolves. Do not shake. Shaking causes foaming, which degrades the peptide.
- The reconstituted solution should be clear. A cloudy or particulate solution should not be used.
Store the reconstituted vial refrigerated at 36–46°F (2–8°C). Kisspeptin-10's short half-life means the reconstituted solution should be used within 14–21 days. Do not freeze a reconstituted vial.
Step 3 — Calculate Your Dose
Your provider will write a specific dose in micrograms (mcg). To calculate the injection volume in milliliters from your vial concentration:
Volume (mL) = Prescribed dose (mcg) ÷ Vial concentration (mcg/mL)
Example: If your provider prescribes 100 mcg and your vial is reconstituted to 2,500 mcg/mL, you inject 0.04 mL (40 microliters). This is a very small volume — use an insulin syringe with markings at the 0.01 mL level for accuracy.
Double-check your calculation before every injection. An error at this step changes the dose substantially. If you're unsure, contact your provider before proceeding — this is not a step to estimate.
Step 4 — Inject
Subcutaneous injection technique for kisspeptin-10 follows the same protocol as other peptide injections:
- Choose a site: abdomen (2 inches from navel), outer thigh, or upper arm. Rotate sites to avoid local tissue irritation.
- Swab the site with an alcohol wipe. Allow to air-dry before injecting.
- Pinch the skin slightly and insert the needle at a 45–90° angle, depending on tissue thickness.
- Inject slowly. Remove the needle at the same angle it entered.
- Apply gentle pressure with a gauze pad. Do not rub — this can cause local irritation.
- Dispose of the needle in a sharps container.
Injection timing matters for kisspeptin-10. Research protocols have used morning injections or pre-sleep injections depending on the hormonal outcome being studied. Your provider will specify timing. Some protocols target specific phases of the natural LH pulse cycle. Follow their instructions, not general online guides.
Step 5 — Track Your Response and Adjust
Kisspeptin-10's clinical value is in the hormonal response it drives. Tracking that response is how your provider knows whether the protocol is working and whether to adjust dose or frequency.
- Labs: Follow-up testosterone, LH, and FSH at 4–6 weeks into a protocol is standard. Your provider orders these.
- Symptom log: Track energy, libido, mood, and any injection site reactions. Report changes through your provider's asynchronous messaging system.
- Dose adjustments: Do not self-adjust the kisspeptin-10 dosage. If labs are insufficient or side effects are significant, your provider modifies the protocol.
For comparison with other peptides used in sexual health and hormone optimization, see the TelosRX PT-141 vs. kisspeptin comparison. If you're evaluating kisspeptin as part of a broader protocol, the peptides for libido research guide covers the relevant evidence landscape.
Kisspeptin-10 Side Effects
In human IV research, kisspeptin-10 has been generally well tolerated at doses used in studies. Reported side effects at clinical doses include:
- Flushing or mild warmth at injection site
- Transient headache
- Nausea (uncommon at low doses)
- Transient changes in cardiovascular parameters at high IV doses in some studies
Long-term subcutaneous use data in humans is limited — most kisspeptin-10 research involves short infusion protocols, not prolonged self-administered courses. Unknown long-term risks are a real consideration. This is another reason provider supervision matters: a prescribing provider monitors for unexpected effects and adjusts or discontinues as needed.
Research on kisspeptin-10 is ongoing via ClinicalTrials.gov.
Is Kisspeptin-10 FDA-Approved?
No. Kisspeptin-10 is not FDA-approved for any indication.
It is a compounded peptide prepared under federal compounding regulations at a licensed compounding pharmacy. As a compounded medication, it is not FDA-approved, not subject to the same quality or efficacy review as an approved drug, and prescribed only when a licensed provider determines clinical appropriateness through a provider-issued prescription.
FDA approval status does not determine whether a compound is useful or safe — it determines whether the FDA has reviewed formal efficacy and safety data for a specific indication. Many peptides under active research have not gone through that process. Your provider's role is to evaluate whether the existing evidence is sufficient to support clinical use in your case.
Frequently Asked Questions
What is the standard kisspeptin-10 dosage for subcutaneous use?
There is no formally validated subcutaneous dosing protocol backed by human RCT data. Clinical providers typically reference IV study doses (around 1 µg/kg) and adapt them for subcutaneous administration. Flat doses used in practice range from 100–500 mcg per injection, but these are provider-specific, not standardized, and subject to medical approval by a licensed provider.
How often do you inject kisspeptin-10?
Protocol frequency varies based on the clinical goal. Some research uses single acute doses; longer protocols may involve injections 2–3 times per week. Your provider specifies the schedule based on your hormone labs and protocol objectives. Kisspeptin-10's short half-life means frequent dosing may be needed for sustained effect.
Can women use kisspeptin-10?
Kisspeptin-10 research includes both male and female subjects. In women, kisspeptin stimulates LH and FSH, which influence estrogen and progesterone cycles. Research has explored its role in hypogonadotropic amenorrhea and fertility support. Female dosing protocols differ from male protocols. Provider evaluation and provider-issued prescription are required.
How does kisspeptin-10 differ from PT-141?
PT-141 (bremelanotide) works on melanocortin receptors to directly increase sexual arousal. Kisspeptin-10 works upstream at the hypothalamic level to stimulate natural LH and testosterone production. They target different mechanisms — PT-141 is more directly focused on arousal signaling, while kisspeptin-10 is more focused on the hormonal substrate that underlies libido and reproductive health.
How long does it take for kisspeptin-10 to work?
In IV research, LH responses to kisspeptin-10 are detectable within 10–20 minutes and peak around 60 minutes post-injection. Subcutaneous absorption is slower. For longer-term hormonal effects — rising testosterone or improved LH pulse patterns — labs at 4–6 weeks into a supervised protocol give the clearest picture.
Can I buy kisspeptin-10 without a prescription?
Legitimate compounding pharmacies dispense kisspeptin-10 only with a provider-issued prescription. Research-labeled peptides sold online without prescription requirements are not prepared under the same quality standards and are not legal for human use. TelosRX works exclusively with licensed compounding pharmacies and requires provider review before any prescription is issued.
Is kisspeptin-10 the same as kisspeptin-54?
No. Kisspeptin-54 is the longer isoform; kisspeptin-10 is the 10-amino-acid active fragment. Both bind the same receptor (KISS1R) and stimulate LH release, but they have different half-lives and potency profiles. Most research on LH stimulation for hormone optimization uses kisspeptin-10 due to its shorter, more predictable profile. Research on kisspeptin-54 is more common in fertility endocrinology.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Start your private evaluation at TelosRX.